News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
305,230 Results
Type
Article (18744)
Company Profile (164)
Press Release (286322)
Section
Business (84116)
Career Advice (107)
Deals (15314)
Drug Delivery (49)
Drug Development (57037)
Employer Resources (30)
FDA (9626)
Job Trends (6387)
News (163544)
Policy (13983)
Tag
Academia (1075)
Alliances (24389)
Alzheimer's disease (818)
Antibody-drug conjugate (ADC) (51)
Approvals (9565)
Artificial intelligence (56)
Bankruptcy (85)
Best Places to Work (5689)
Biotechnology (129)
Breast cancer (89)
Cancer (751)
Cardiovascular disease (52)
Career advice (99)
CAR-T (67)
Cell therapy (218)
Clinical research (46021)
Collaboration (225)
Compensation (81)
COVID-19 (1106)
C-suite (53)
Cystic fibrosis (71)
Data (661)
Diabetes (84)
Diagnostics (2096)
Earnings (31154)
Events (47792)
Executive appointments (156)
FDA (9934)
Funding (166)
Gene editing (51)
Gene therapy (165)
GLP-1 (348)
Government (1602)
Healthcare (8879)
Infectious disease (1138)
Inflammatory bowel disease (84)
IPO (7593)
Job creations (931)
Job search strategy (93)
Layoffs (187)
Legal (2094)
Liver cancer (51)
Lung cancer (140)
Manufacturing (100)
Medical device (5053)
Medtech (5057)
Mergers & acquisitions (7806)
Metabolic disorders (246)
Neuroscience (1011)
NextGen Class of 2024 (2434)
Non-profit (1363)
Northern California (775)
Obesity (143)
Opinion (79)
Parkinson's disease (60)
Patents (58)
People (23195)
Phase I (14125)
Phase II (20545)
Phase III (15711)
Pipeline (160)
Postmarket research (1686)
Preclinical (5316)
Press Release (48)
Radiopharmaceuticals (181)
Rare diseases (169)
Real estate (1969)
Regulatory (11105)
Research institute (1260)
Southern California (661)
Startups (1761)
United States (6921)
Vaccines (185)
Weight loss (108)
Date
Today (137)
Last 7 days (523)
Last 30 days (1891)
Last 365 days (23298)
2024 (19226)
2023 (24967)
2022 (31433)
2021 (32547)
2020 (28206)
2019 (20586)
2018 (15298)
2017 (16613)
2016 (14530)
2015 (17028)
2014 (11717)
2013 (9002)
2012 (9249)
2011 (9418)
2010 (8515)
Location
Africa (199)
Asia (29659)
Australia (4296)
California (1680)
Canada (555)
China (165)
Colorado (54)
Connecticut (73)
Europe (45601)
Florida (227)
Georgia (53)
Illinois (119)
Indiana (91)
Maryland (287)
Massachusetts (1459)
Minnesota (144)
New Jersey (547)
New York (526)
North Carolina (440)
Northern California (775)
Ohio (77)
Pennsylvania (482)
South America (287)
Southern California (661)
Texas (211)
Washington State (228)
305,230 Results for "immunovative therapies ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immunovant Provides Update on Graves’ Disease Development Program
September 9, 2024
·
6 min read
Business
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024.
May 29, 2024
·
14 min read
Press Releases
Immunovant to Host Graves’ Disease Program Update on September 9, 2024
September 5, 2024
·
1 min read
Policy
Immunovant Awarded U.S. Patent for IMVT-1402
Immunovant, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 for IMVT-1402, the Company’s second-generation antibody targeting the neonatal fragment crystallizable receptor.
March 12, 2024
·
4 min read
Press Releases
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
October 8, 2024
·
3 min read
Press Releases
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
October 29, 2024
·
1 min read
Press Releases
Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies
October 30, 2024
·
5 min read
Pharm Country
Immunovant Announces Pricing of $450 Million Common Stock Financing
Immunovant, Inc. announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions.
September 27, 2023
·
4 min read
Business
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024
August 6, 2024
·
10 min read
Business
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.
February 12, 2024
·
11 min read
1 of 30,523
Next
